AcelRx Pharmaceuticals (ACRX) Posts Narrower than Expected Q4 Loss of 33c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q4 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand